Conversion of £1.5m of Convertible Loan Notes

Kromek Group PLC

05 February 2024

 

5 February 2024 

Kromek Group plc 

("Kromek" or the "Company" or the "Group") 

Conversion of £1.5m of Convertible Loan Notes

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that two holders of the convertible loan notes ("Loan Notes") issued in August 2022 have elected to convert them into new ordinary shares of 1 penny each in the Company ("Ordinary Shares") at conversion prices of 6.3 pence and 7.1 pence, per Ordinary Share.

Including accrued interest, the Loan Note holders are converting £1,509,211 of debt into 23,639,520 new Ordinary Shares and accordingly these new Ordinary Shares have been issued and allotted by the board.

The issue prices of 6.3 and 7.1 pence per new Ordinary Share represent the closing price of the Company's Ordinary Shares on AIM on 31 January 2024 and 2 February 2024, respectively, being the repayment date of the convertible loan note facilities.

Application has been made for the 23,639,520 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 9 February 2024 ("Admission").

The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 623,886,340 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 623,886,340 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:  Kromek Group plc  Arnab Basu, CEO  Paul Farquhar, CFO  [phone]  Cavendish Capital Markets Limited (Nominated Adviser and Broker)   Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance  Tim Redfern - ECM Michael Johnson/Tamar Cranford-Smith - Sales [phone]  Gracechurch Group (Financial PR)  Harry Chathli/Claire Norbury/Henry Gamble  [phone]

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

END